What smart money is saying about EssilorLuxottica
ESLOY
No fund has written a full thesis on EssilorLuxottica in our archive, but 1 fund letter reports a position in it, most recently Clearbridge International Growth ADR Strategy in December 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
1
Bought
0
Sold
1
Letter
Position history
Every position in EssilorLuxottica on record in the archive was reported in Q4 2025, across 1 fund letter, with 1 buy (opened or added).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q4 2025 | 1 | 1 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position · 1 move
- December 2025
“Portfolio Positioning The health care sector was a focus of activity in the quarter with the repurchases of EssilorLuxottica and Galderma Group and the addition of Roche.”
EssilorLuxottica
Read the letters behind these EssilorLuxottica positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger